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SUMMARY
Aims: In this study, we compared the glucose-lowering effectiveness of insulin
analogues and their combination according to baseline glycemic status in patients
with type 2 diabetes (T2D) from the A1chieve
 study conducted in Korea.
Methods: This sub-analysis from the A1chieve
 study was a 24-week prospective,
multicenter, non-interventional, open-labelled study. Of the 4058 patients, 3074
patients who had their HbA1c level measured at baseline were included in this
sub-analysis. We classified patients into three groups according to baseline HbA1c
levels: group I (HbA1c < 7.5%), group II (7.5% ≤ HbA1c < 9.0%) and group III
(HbA1c ≥ 9.0%). Results: Patients in group I showed no significant HbA1c reduc-
tion with any insulin regimens (detemir, aspart, detemir and aspart or biphasic as-
part 30 (Novo Nordisk A/S, DK-2880 Bagsværd, Denmark) after 24 weeks of
treatment. In group II, although HbA1c was decreased for all insulin regimens,
there was no difference in mean HbA1c reduction among the four insulin regimens.
In patients with a high baseline HbA1c level (group III), mean HbA1c reduction was
the greatest in patients on a basal-bolus regimen (detemir and aspart, 3.50%)
and lowest in patients on a bolus regimen (aspart, 1.81%; p < 0.001).
Conclusion: For optimal glycaemic control, a basal-bolus regimen may be ade-
quate for Korean patients with poorly controlled T2D (HbA1c ≥ 9.0%).
What’s known
• In the A1chieve study, treatment with insulin
analogues was associated with marked
improvements in glycemic, blood pressure and
lipid control without increasing hypoglycemic
rates or body weight.
• In the A1chieve study conducted in Korea,
treatment with insulin analogues showed
reductions in HbA1c, fasting plasma glucose, and
postprandial plasma glucose. In addition, the
overall quality of life score was improved while
no major hypoglycemic episodes were observed.
What’s new
• No significant HbA1c reduction was observed
with any insulin regimens in Korean patients with
relatively well controlled type 2 diabetes (T2D;
HbA1c < 7.5%).
• For optimal glycemic control, a basal-bolus
regimen may be adequate for Korean patients
with poorly controlled T2D (HbA1c ≥ 9.0%).
Introduction
To determine if insulin analogues are beneficial when
treating patients with type 2 diabetes (T2D), the
A1chieve
 study was conducted as a 6-month prospec-
tive, multinational (28 countries), open-labelled,
observational study. The study enrolled 66,726
patients with T2D, both insulin and non-insulin users
who were started on detemir, aspart or biphasic aspart
30. The study results showed that insulin analogue
therapy was associated with marked improvements in
glycemic, blood pressure and lipid control without
increasing hypoglycaemic rates or body weight (1). In
the A1chieve
 study conducted in Korea, the treat-
ment with insulin analogues showed beneficial 24-
week reductions in HbA1c, fasting plasma glucose
(FPG) and postprandial plasma glucose (PPG)
(1.6  2.2%, 2.5  4.7 and 4.0  6.4 mmol/l,
respectively). In addition, the overall quality of life
score was improved, while no major hypoglycaemic
episodes were observed and the rate of minor hypogly-
caemic episodes marginally decreased (2).
Although the A1chieve
 study in Korea demon-
strated the benefits of insulin analogues, individua-
lised recommendations regarding the optimal
approach to insulin analogue therapy was not pro-
vided, including types of insulin formulation [basal,
rapid-acting (henceforth bolus), basal and bolus and
biphasic insulin] and insulin regimen (starting doses,
number of injections). In addition, few reports exist
regarding the characteristics of Korean patients with
T2D who respond adequately to insulin analogue
therapy (3–5).
Therefore, in this sub-analysis from the A1chieve

study, we compared the glucose-lowering effective-
ness of insulin analogues and their combination
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according to baseline glycemic status in Korean
patients with T2D.
Patients and methods
Patients and study design
The study population and design were described in a
previous report (2). Briefly, Korean patients with
T2D, including those who were started on biphasic
aspart 30, detemir or aspart within the 4 weeks prior
to the initiation of the study were eligible to partici-
pate in the study. Patients with a hypersensitivity to
the study products or women who were pregnant,
breast feeding or had the intention of becoming
pregnant within the next 6 months were excluded
from the A1chieve
 study. The cessation of study
insulin was at the discretion of the patients’ physi-
cian, who also determined all subsequent treatments
(aspart, biphasic aspart 30, or detemir) according to
standard protocol. Patients were allowed to withdraw
from the study at any time. The protocol was
reviewed and approved by independent Institutional
Review Boards in the study sites and all participants
gave written informed consent before any trial-
related activity. The study was performed in accor-
dance with the Declaration of Helsinki and the
guidelines for Good Pharmacoepidemiology Prac-
tices. A1chieve
 was registered at Clinicaltrial.gov
with the identifier NCT00869908.
The A1chieve
 study in Korea was a 24-week
prospective, multicentre (104 sites in Korea), non-
interventional, real clinical practice setting and
open-labelled study. Data were collected at baseline,
interim visit (approximately 12 weeks after the base-
line visit) and final visit (approximately 24 weeks
after the baseline visit). During the study period, the
primary end-point was serious adverse drug reac-
tions including major hypoglycaemic events, and
secondary study end-points were effectiveness and
safety. The secondary effectiveness end-points
included changes in FPG, PPG after breakfast, HbA1c
and lipid profile from baseline to interim and final
visit. The safety end-points were as follows: change
in number of hypoglycaemic events and nocturnal
hypoglycaemic events in the last 4 weeks before the
interim and final visits compared with the last
4 weeks before baseline visit and the number of
adverse drug reactions. A hypoglycaemic event was
defined either as symptoms of hypoglycaemia that
resolved with oral carbohydrate intake, glucagon and
intravenous glucose or any symptomatic or asymp-
tomatic plasma glucose < 3.1 mmol/l. A nocturnal
hypoglycaemic event was defined as an individua-
lised symptomatic event that occurred while the
patient was asleep.
Analysis design
Based on the aims of this study, we first classified
patients into three groups according to baseline HbA1c
levels: group I (HbA1c < 7.5%), group II
(7.5% ≤ HbA1c < 9.0%) and group III (≥ 9.0%). Sec-
ondly, we subclassified each group into four subgroups
according to type or regimen of insulin analogues:
subgroup I used a basal regimen (detemir), subgroup
II used a bolus regimen (aspart), subgroup III used a
basal-bolus regimen (detemir and aspart) and sub-
group IV used a biphasic regimen (biphasic aspart 30).
Statistical analyses
Data were expressed as mean  standard deviation
(SD) or as proportions. The comparison of effective-
ness end-points between HbA1c levels was performed
using ANOVA with repeated measures. The mean
improvement from baseline HbA1c and correspond-
ing 95% confidence interval (CI) was calculated and
compared between treatment groups using ANOVA.
The association between the effect of treatment
group and degree of hyperglycaemia was represented
by n (%) at different levels of HbA1c at the end of
trial. The number of hypoglycaemic episodes was
represented by n (%) and was further classified as
major, minor or nocturnal. Comparison of hypogly-
caemic episodes between the categories was per-
formed using the v2 test. All data were analysed by
Novo Nordisk using SAS (Version 9.1.3, COGNIZANT
TECHNOLOGY SOLUTIONS, Mumbai, India) and p-
values < 0.05 were considered statistically significant.
Results
Baseline characteristics according to baseline
HbA1c levels
Of the 4058 patients who were exposed to the
selected insulin at least once and constituted the full
analysis set (FAS), 3074 patients had their HbA1c
level measured at the baseline and final visit and
2952 patients (72.7% of FAS) who used one of four
insulin analogue regimens were eligible for analysis
(Figure 1).
Baseline characteristics of the study patients accord-
ing to baseline HbA1 levels are shown in Table 1.
Patients were allocated to group I (HbA1c < 7.5%,
n = 302, 173 males, 129 females), group II
(7.5% ≤ HbA1c < 9.0%, n = 877, 449 males, 428
females) or group III (≥ 9.0%, n = 1895, 1049 males,
846 females). The duration of diabetes was significantly
longer in group II (10.0 years, 11.4 years and 9.3 years
in groups I, II and III, respectively; p < 0.001). In addi-
tion, body mass index (BMI) was statistically different
between groups (24.0, 24.6 and 24.2 kg/m2, groups I, II
and III, respectively; p = 0.016).
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Glucose-lowering effectiveness according to
baseline HbA1c levels
In a previous A1chieve
 study report in Korea (2),
HbA1c decreased from 9.7% at baseline to 8.1% at
the 24-week end-point, resulting in a significant
reduction of 1.6  2.2% (p < 0.001). In addition,
the proportion of patients who achieved the target
HbA1c level of < 7.0% increased from 4.8% at base-
line to 18.1% at the 12-week interim and 22.7% at
the 24-week end-point. In terms of type and regimen
of insulin analogues, mean HbA1c reduction was the
greatest in patients on a basal-bolus regimen (levemir
and aspart, 2.2  2.5%; p < 0.001) and lowest in
patients on a bolus regimen (aspart, 0.7  2.3%;
p = 0.036).
In the first step of this study analysis, we classified
patients into three groups according to baseline
HbA1c levels. Table 2 shows the glucose-lowering
effectiveness of insulin analogues according to base-
line HbA1c levels. Baseline mean HbA1c levels were
6.8%, 8.3% and 11.0% in group I (HbA1c < 7.5%),
II (7.5 ≤ HbA1c < 9.0%) and III (HbA1c > 9.0%),
respectively. For Korean patients with relatively well
controlled (group I, HbA1c < 7.5%) and poorly con-
trolled (group II, 7.5% ≤ HbA1c < 9.0%) glucose sta-
tus, physicians prescribed predominantly the basal
regimen (57.2% in group I and 54.6% in group II).
In group I, no significant HbA1c change was
observed in any insulin regimen after 24 weeks of
treatment. In all group II subgroups, the mean
HbA1c was decreased. The mean HbA1c reduction
was greatest in patients with a basal-bolus regimen
and lowest in patients with a bolus regimen (aspart).
However, there were no statistical differences in
mean HbA1c reduction among the four subgroups.
In terms of target HbA1c achievement, the propor-
tion of patients achieving HbA1c < 6.5% and < 7.0%
was the greatest in patients with a basal-bolus regi-
men (11.3%) and bolus regimen (28.6%), respec-
tively. In patients with a very poorly controlled
glucose status (group III, HbA1c > 9.0%), Korean
physicians preferred both basal (46.3%) and biphasic
(40.4%) insulin regimens. In group III, mean HbA1c
reduction was the greatest in patients with a basal-
bolus regimen (3.50%) and lowest in patients with
a bolus regimen (1.81%; p < 0.001).
Enrolled (n = 4058)
Exposed (= Full Analysis Set, n  = 4058)
Novomix ®+/– OAD’s : 1434
Levemir ®+/– OAD’s : 2083
Novorapid ®+/– OAD’s : 164
Basal Insulin + Novorapid ®+/– OAD’s  : 232
Others +/–OAD’s : 145
Withdraw (n = 1055)
Novomix ®+/– OAD’s : 371  (0*/245/126)
Levemir ®+/– OAD’s : 541 (0*/363/178)
Novorapid ®+/– OAD’s : 41  (0*/23/18)
Basal Insulin + Novorapid ®+/– OAD’s  : 69  (0*/54/15)
Others +/–OAD’s : 33  (0*/25/8)
Completed (n = 3003)
Novomix ®+/– OAD’s : 1063
Levemir ®+/– OAD’s                       : 1542
Novorapid ®+/– OAD’s : 123
Basal Insulin + Novorapid ®+/– OAD’s  : 163
Others +/–OAD’s : 112
Efficacy Analysis Set (n = 2940)
Novomix ®+/– OAD’s : 1052
Levemir ®+/– OAD’s : 1528
Novorapid ®+/– OAD’s : 108
Basal Insulin + Novorapid ®+/– OAD’s  : 150
Others +/–OAD’s   : 102
Figure 1 Flow diagram of study
ª 2014 The Authors. International Journal of Clinical Practice Published by John Wiley & Sons Ltd.
Int J Clin Pract, November 2014, 68, 11, 1338–1344
1340 Glycemic efficacies of insulin analogue regimens
With respect to the effectiveness of insulin ana-
logues based on baseline HbA1c levels, the glucose-
lowering effectiveness (0.01% to 0.42% reduction
in HbA1c level) was minimal or equivalent in group
I (HbA1c < 7.5%, mean HbA1c level of 6.8%). In
addition, the percentage of patients reaching a target
HbA1c level of < 7.0% was not different among the
four insulin regimens (23.8–36.8%). In the poorly
controlled T2D group II patients
(7.5% ≤ HbA1c ≤ 9.0%, mean HbA1c level of 8.3%),
the HbA1c reduction effectiveness was perceivable
(0.04% to 0.92% reduction in HbA1c level). The
percentage of patients reaching a target HbA1c level
of < 7.0% was significantly higher in the subgroup
using bolus (28.6%) and basal-bolus (22.6%) regi-
mens (p = 0.049). In the very poorly controlled T2D
group III patients (HbA1c > 9.0%, mean HbA1c level
of 11.0%), the HbA1c reduction effectiveness was
pronounced (1.81% to 3.50% reduction in HbA1c
level). The percentage of patients reaching the target
HbA1c level of < 7.0% was not significantly different
among the four subgroups (8.6–11.4%). Despite sta-
tistical insignificance, the basal-bolus regimen
showed the highest percentage of patients reaching
the target HbA1c level of < 7.0% (11.4%). Regarding
the use of basal-bolus regimen in clinical practice,
except for the patients achieving the HbA1c level of
< 7.0% in group II, higher HbA1c reduction effec-
tiveness and higher percentages of Korean patients
that achieved target HbA1c levels < 6.5% or < 7.0%
were found in the poorly or very poorly controlled
T2D groups II and III, respectively.
Hypoglycaemic events and body weight change
according to baseline HbA1c levels
Although hypoglycaemic events were similar across
the different insulin regimens in group I, hypoglycae-
mic events were most frequently observed in patients
with basal-bolus regimen in group II (17.0%) and
group III (14.0%; both p < 0.001). In terms of body
weight change, treatment with basal-bolus or bipha-
sic regimens showed greater weight gain compared
with other insulin modalities in group III
(p = 0.036); however, differences in body weight
change were not observed in group I and II accord-
ing to different insulin regimens. Next, we deter-
mined the best insulin modality allows patients to
meet their glycemic goals while avoiding the risk of
Table 1 Baseline clinical and biochemical characteristics of the study patients
HbA1c
Group I
< 7.5%
Group II
7.5–9.0%
Group III
≥ 9.0% p-value
Number 302 877 1895
Male (%) 173 (57.3) 449 (51.2) 1049 (55.1) 0.069*
Age (years) 58.1 (13.3) 58.2 (11.7) 56.2 (13.5) < 0.001†
Weight (kg) 63.9 (11.2) 64.6 (11.0) 64.1 (11.9) 0.581†
BMI (kg/m2) 24.0 (3.6) 24.6 (3.5) 24.2 (3.7) 0.016†
Diabetes duration (years) 10.0 (8.0) 11.4 (7.7) 9.3 (7.7) < 0.001†
HbA1c (mmol/mol) 51.3 (5.4) 66.9 (4.6) 96.3 (18.3) < 0.001
†
FPG (mmol/l), before
Breakfast 8.3 (3.4) 8.9 (3.1) 11.8 (4.7) < 0.001†
Lunch 11.6 (5.1) 10.3 (3.4) 13.3 (5.6) < 0.001†
Dinner 10.7 (4.2) 11.9 (4.6) 13.8 (5.5) < 0.001†
PPG2 (mmol/l) after
Breakfast 12.3 (4.3) 13.8 (4.7) 16.9 (6.0) < 0.001†
Lunch 12.0 (5.1) 13.7 (4.2) 16.5 (6.0) < 0.001†
Dinner 12.0 (4.1) 13.4 (4.3) 14.2 (4.7) 0.019†
Prior OADs (%)
Metformin 164 (54.3) 622 (70.9) 1345 (71.0) < 0.001*
Sulfonylureas 129 (42.7) 499 (56.9) 960 (50.7) < 0.001*
Glinide 52 (17.2) 134 (15.3) 228 (12.0) < 0.001*
Thiazolidinediones 18 (6.0) 52 (5.9) 132 (7.0) 0.086*
DPP-4 inhibitors 12 (4.0) 32 (3.6) 85 (4.5) 0.045*
a-glucosidase inhibitor 65 (21.5) 261 (29.8) 484 (25.5) 0.030*
*Data are expressed as frequency (%) and the p-value estimated based on the v2 test. †Data are expressed as mean (SD) and the
p-value estimated based on one way ANOVA. BMI, body mass index; FPG, fasting plasma glucose; PPG2, postprandial glucose 2 h;
OAD, oral antihyperglycaemic drug; DPP, dipeptidyl peptidase; NS, not significant.
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hypoglycaemia according to different insulin regi-
mens. The percentage of patients reaching a target
HbA1c level of < 7.0% without hypoglycaemia was
greater in patients on a bolus regimen in group II
(25.7%). In group III, although statistically signifi-
cant, the achievement of glycemic goals without hyp-
oglycaemia was similar across the insulin regimens
(Table 3).
Discussion
Despite little controversy regarding the need for opti-
mal glycemic control in insulin therapy for patients
with poorly controlled diabetes (6–8), which insulin
therapy treatment modality allows patients to best
meet and maintain individualised glycemic goals
while avoiding the risk of hypoglycaemia remains
unclear (9). Furthermore, most studies recommend
the insulin therapy to be based on HbA1c levels
(6–8). In terms of its non-randomised, non-interven-
tional study design, the present study has both
strengths and limitations that could be comple-
mented by further investigations. Although rando-
mised clinical trials are considered the gold standard,
the non-interventional study design evaluates effec-
tiveness and optimal regimens in real clinical practice
(4,10). Based on a previous report (2), treatment
with insulin analogues (aspart, biphasic aspart 30,
detemir, or detemir and aspart) reduced HbA1c, FPG
and PPG levels during the 24-week of treatment per-
iod (1.6  2.2%, 2.5  4.7 and 4.0  6.4 mmol/l,
respectively).
To date, scientific reports investigating optimal
approaches to treatment with insulin analogues and
comparing their glucose-lowering effectiveness in real
practice have been lacking in Korean patients with
T2D. Therefore, we investigated current decision-
making on the initiation of insulin analogues based
on baseline HbA1c levels and the effectiveness of
insulin regimens based on reductions in HbA1c, as
well as the proportion of patients reaching target
HbA1c < 7.0%. By understanding daily practice set-
tings, we hope to suggest the optimal insulin ana-
logue-based glycemic control in Korean patients with
T2D.
Regarding current decisions on the initiation of
insulin analogues, approximately 88.5% of patients
in this observational study initiated insulin analogue
therapy with HbA1c levels greater than 7.5% and a
disease duration of approximately 10.0 years.
According to the consensus statements of the Ameri-
can Diabetes Association and the European Associa-
tion for the Study of Diabetes (11), insulin initiation is
recommended when FPG levels are above 250 mg/dl,
Table 2 Glucose-lowering effectiveness according to type or regimen of insulin analogues
Basal regimen
(n = 1531)
Bolus regimen
(n = 112)
Basal-bolus regimen
(n = 187)
Biphasic regimen
(n = 1122) p-value
Group I (n) 173 19 20 80
Baseline A1c (mmol/mol) 51.7 (5.3) 50.9 (5.1) 48.4 (7.3) 51.5 (5.3) 0.084*
A1c change (mmol/mol, 95% CI) 1.0 (0.9, 3.0) 2.3 (2.9, 7.4) 0.2 (7.0, 6.7) 4.6 (0.4, 8.9) 0.058*
A1c < 48 (mmol/mol) 31 (17.9) 2 (10.5) 1 (5.0) 8 (10.0) 0.28†
A1c < 53 (mmol/mol) 51 (29.5) 7 (36.8) 6 (30.0) 19 (23.8) 0.27†
A1c < 58 (mmol/mol) 73 (42.2) 10 (52.6) 7 (35.0) 27 (33.8) 0.26†
Group II (n) 479 35 53 275
Baseline A1c (mmol/mol) 66.7 (4.6) 65.6 (5.2) 66.8 (4.9) 67.3 (4.5) 0.12*
A1c change (mmol/mol, 95% CI) 5.7 (7.0, 4.4) 0.5 (10.4, 9.4) 10.0 (14.1, 6.0) 5.8 (7.4, 4.2) 0.11*
A1c < 48 (mmol/mol) 12 (2.5) 2 (5.7) 6 (11.3) 9 (3.3) 0.022†
A1c < 53 (mmol/mol) 56 (11.7) 10 (28.6) 12 (22.6) 35 (12.7) 0.049†
A1c < 58 (mmol/mol) 129 (26.9) 12 (34.3) 22 (41.5) 75 (27.3) 0.16†
Group III (n) 879 58 114 767
Baseline A1c (mmol/mol) 94.1 (16.7) 93.8 (13.2) 102.0 (20.7) 98.0 (19.4) < 0.001*
A1c change (mmol/mol, 95% CI) 26.2 (28.4, 24.1) 19.8 (31.1,8.6) 38.2 (46.1, 30.3) 26.4 (29.0, 23.8) < 0.001*
A1c < 48 (mmol/mol) 40 (4.6) 4 (6.9) 10 (8.8) 37 (4.8) 0.23†
A1c < 53
(mmol/mol)
85 (9.7) 5 (8.6) 13 (11.4) 66 (8.6) 0.61†
A1c < 58
(mmol/mol)
137 (15.6) 10 (17.2) 22 (19.3) 111 (14.5) 0.37†
Data are expressed as mean (SD), mean (95% CI), or frequency (%). *Data are expressed as mean (SD) and the p-value estimated based on one way ANOVA.
†Data are expressed as frequency (%) and the p-value estimated based on the chi-square test.
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random glucose levels are above 300 mg/dl, or HbA1c
is above 10.0%. However, insulin could also be
considered whenever HbA1c is above 8.5% and
patients are already receiving a treatment to achieve a
more effective control. Considering the status of
glycemic control determined by HbA1c levels, current
decisions on the initiation of insulin analogues are
within limits of the consensus reached by the Korean
medical practitioners.
Because the underlying pathophysiological nature
of T2D involves initially increased insulin resistance
and decreased insulin secretion with ongoing pro-
gressive deterioration in pancreatic b-cell function
and resulting in pancreatic islet exhaustion, which
corresponds clinically with deteriorating hyperglyca-
emia (12–14), early initiation of insulin therapy
might be considered the optimal approach. In addi-
tion, because of T2D characteristics in the Korean
population where secretory dysfunction of pancreatic
b-cells is the major underlying pathophysiology for
the development and aggravation of hyperglycaemia
(12,15,16), an insulin regimen advocating control of
postprandial hyperglycaemia on an individual basis
might be an important area of study in the Korean
population (5).
This study had several limitations. First, this study
was performed on Korean subjects and thus, deter-
mining the glucose-lowering effectiveness of insulin
analogues and their combination in other ethnicities
or study populations is necessary. Second, we did
not consider the effect of other confounders poten-
tially affecting glucose-lowering effectiveness and
adverse effects of different insulin regimens, includ-
ing age, gender, BMI, duration of diabetes and con-
comitant oral hypoglycaemic agents.
In summary, this observational study provides
important information on how pharmaceutical insu-
lin therapies perform in real clinical practice. Physi-
cians might decide to start insulin therapy in
patients with T2D if the HbA1c level is greater than
7.5%. Based on our results, we suggest that a basal-
bolus regimen might be adquate in Korean patients
with poorly controlled T2D (HbA1c > 9.0%). A fur-
ther large-scale, randomised, interventional study
Table 3 Safety issues according to type or regimen of insulin analogues
Basal regimen
(n = 1531)
Bolus regimen
(n = 112)
Basal-bolus
regimen (n = 187)
Biphasic regimen
(n = 1122) p-value
Group I (n) 173 19 20 80
Any hypoglycaemia (%)* 7 (4.1) 2 (10.5) 1 (5.0) 5 (6.3) 0.11†
Body weight at baseline (kg) 64.3 (11.4) 67.6 (10.0) 61.9 (11.6) 62.5 (11.1) 0.43‡
Body weight change (kg) 0.2 (2.0) 1.1 (2.9) 0.5 (1.2) 0.0 (3.3) 0.28‡
A1c < 53 mmol/mol without
any hypoglycaemia (%)
48 (27.8) 6 (31.6) 6 (30.0) 17 (21.3) < 0.001†
A1c < 58 mmol/mol without
any hypoglycaemia (%)
69 (39.9) 9 (47.4) 7 (35.0) 24 (30.0) < 0.001†
Group II (n) 479 35 53 275
Any hypoglycaemia (%)* 26 (5.4) 2 (5.7) 9 (17.0) 29 (10.6) < 0.001†
Body weight at baseline (kg) 64.5 (10.6) 67.2 (15.1) 64.9 (12.4) 65.4 (11.5) 0.53‡
Body weight change (kg) 0.1 (2.6) 0.3 (2.8) 1.4 (2.3) 0.3 (2.9) 0.08‡
A1c < 53 mmol/mol without
any hypoglycaemia (%)
51 (10.7) 9 (25.7) 8 (15.1) 31 (11.3) < 0.001†
A1c < 58 mmol/mol without
any hypoglycaemia (%)
118 (24.6) 11 (31.4) 15 (28.3) 63 (22.9) < 0.001†
Group III (n) 879 58 114 767
Any hypoglycaemia (%)* 45 (5.1) 6 (10.3) 16 (14.0) 67 (8.7) < 0.001†
Body weight at baseline (kg) 63.9 (11.6) 63.8 (8.9) 63.0 (10.7) 64.3 (11.9) 0.80‡
Body weight change (kg) 0.6 (3.0) 0.7 (2.4) 1.0 (3.6) 1.3 (3.4) 0.036‡
A1c < 53 mmol/mol without
any hypoglycaemia (%)
77 (8.8) 4 (6.9) 9 (7.9) 60 (7.8) < 0.001†
A1c < 58 mmol/mol without
any hypoglycaemia (%)
123 (14.0) 8 (13.8) 17 (14.9) 100 (13.0) < 0.001†
Data are expressed as mean (SD) or frequency (%). *Hypoglycaemic events were assessed at last visit. †Data are expressed as
frequency (%) and the p-value estimated based on the v2 test. ‡Data are expressed as mean (SD) and the p-value estimated based on
one way ANOVA.
ª 2014 The Authors. International Journal of Clinical Practice Published by John Wiley & Sons Ltd.
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should be performed to clarify the effectiveness and
safety of a basal-bolus regimen in Korean patients
with T2D.
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